JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares
NASDAQ: ZJYL · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES
Updated 2026-04-30
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares (ZJYL) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for ZJYL.
Current price exceeds what fundamentals support. Risk/reward skewed unfavorably.
ZJYL historical valuation range
Where current P/E sits in ZJYL's own 5Y range.
ZJYL intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Standard discounted cash flow models produce unreliable output for unprofitable or near-breakeven companies. Revenue-based multiples such as P/S and EV/Sales, combined with the historical valuation position above, give a more reliable read for this stock.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
ZJYL valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
Current: 11.50x
P/S Ratio — History
Current: 0.87x
Is ZJYL overvalued in 2026?
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares (ZJYL) currently trades at $2.17 per share with a market capitalization of $18,002,900.00. Based on our multi-factor framework, the stock appears richly valued with a Smart Value Score of 36/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
The stock trades at a P/E ratio of 11.5x, below its 5-year median of 39.9x.
Looking at its own history, ZJYL is currently trading cheaper than 75% of the last 5Y on P/E. This places it in the 25th percentile of its historical range, a reasonable but unremarkable position.
A standard DCF model does not produce reliable output for ZJYL under current conditions. For unprofitable or near-breakeven companies, revenue-based multiples such as EV/Sales and historical P/S percentile are more informative than intrinsic value calculations.
Financial quality is a concern. The Piotroski F-Score of 0/9 flags weakening fundamentals that deserve closer scrutiny before the valuation case can be fully trusted.
Bottom line: ZJYL appears richly valued on our framework, with a Smart Value Score of 36/100. At current levels the risk/reward is skewed against the buyer. A materially lower price or significant operational improvement would be needed to change the picture.
Frequently asked questions
Is ZJYL overvalued in 2026?
Based on a Smart Value Score of 36/100, ZJYL appears overvalued. Current price exceeds what fundamentals currently justify.
What is ZJYL's fair value?
Standard DCF is unreliable for ZJYL due to its current profitability profile. Revenue-based approaches such as EV/Sales or historical P/S percentile are more informative for this stock.
What P/E ratio does ZJYL trade at?
ZJYL trades at a P/E of 11.5x on trailing twelve-month earnings, compared to its 5-year median of 39.9x.
Is ZJYL a buy based on valuation?
WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 36/100 reflects the combined read on growth, quality, and price. The profile skews cautious. Consider waiting for a better price or clearer operational improvement.
How does ZJYL's valuation compare to its history?
On P/E, ZJYL currently sits in the 25th percentile of its own 5Y range. That is below its long-run median relative to where it has traded over the period.
What is ZJYL's Smart Value Score?
ZJYL's Smart Value Score is 36/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.